Canine Freeze-Dried Plasma Is Here: What the FDA's December 2025 Decision Means for Working Dog Resuscitation

On December 18, 2025, the U.S. Food and Drug Administration's Center for Veterinary Medicine completed a risk review of the first freeze-dried plasma product ever evaluated by the agency for use in dogs (FDA CVM, Dec 18, 2025). Mantel Technologies' canine freeze-dried plasma — the product the U.S. Army Medical Materiel Development Activity (USAMMDA) has been working to field since 2022 — can now move from training kits to operational use. For working-dog handlers, special operations medics, K9 trauma teams, and tactical veterinarians, this is the most important shift in canine combat casualty care since the publication of the K9TCCC framework. This article is the primary-source breakdown of what the FDA actually decided (it is not what most early media coverage says), where cFDP fits in the K9TCCC fluid hierarchy, what injuries cFDP treats and what it does not, and how units should prepare to integrate it under current prescribing law.

What did the FDA actually decide about Mantel's canine freeze-dried plasma on December 18, 2025?

The CVM update describes a regulatory pathway that exists between full FDA approval and the unregulated extralabel use that has historically dominated canine emergency blood products. The agency evaluated Mantel's cFDP against the broader scientific literature on freeze-dried plasma (which has been used in humans for decades and increasingly in veterinary medicine over the last 10 years) and against existing plasma products such as fresh frozen plasma. The conclusion was that the developer "properly identified and appropriately mitigated the potential risks associated with the product, the product has similar properties to other plasma products, and FDA has no additional safety concerns" (FDA CVM).

The product itself is delivered as a kit: 20 grams of lyophilized pooled allogeneic canine plasma in a 250 mL single-use bag, 250 mL of sterile water for injection for reconstitution, and an IV administration set. Shelf life is at least one year at room temperature — the operational property that has made freeze-dried plasma the standard far-forward blood product in human combat casualty care since the French FLYP and German LyoPlas G fielded in NATO operations. The CVM update is explicit that the product is intended "for intravenous use in acute medical emergencies in dogs when whole blood products may not be available, such as with trauma cases with military working dogs and dogs in remote locations."

What this regulatory posture means in practice:

• Prescription-only. Acquisition runs through a licensed veterinarian. A unit cannot stock cFDP without a veterinary prescribing relationship.
• Specialized veterinary expertise required. The FDA language is explicit: "specialized veterinary medical expertise is necessary for the safe use of the product." Operational planning needs to incorporate that expertise — typically a Department of Defense veterinarian or a contracted civilian veterinarian for non-DoD K9 teams.
• Not equivalent to full FDA approval. Statements that the FDA "approved" cFDP are factually wrong. The correct phrasing for procurement and training documentation is "FDA risk-reviewed; no objection to marketing."
• Liability framework still developing. For non-military K9 teams (police, search-and-rescue, federal agency), prescribing veterinarian relationships and unit medical-director protocols are the controlling legal documents. Expect the law and the standard of care to mature over the next 24 months.

How is canine freeze-dried plasma different from whole blood, fresh frozen plasma, or crystalloid in a dog trauma resuscitation?

The mechanism of trauma-induced coagulopathy is the same in dogs as it is in humans: hemorrhage drives loss of platelets and clotting factors, hypoperfusion drives endothelial activation and fibrinolysis, and the resulting "diamond of death" (hypothermia, acidosis, coagulopathy, hyperfibrinolysis) is what kills a salvageable patient (JTS MWD Transfusion CPG, ID 77, 2019). Plasma corrects two of those four variables — the coagulopathy and the hypovolemia. It does not warm the patient (active warming does) and it does not correct acidosis (perfusion does). Plasma is therefore a force multiplier inside a complete resuscitation framework, not a single-product solution.

The 2019 JTS Clinical Practice Guideline for transfusion in military working dogs documents the underlying preference order for canine blood products in operational settings: fresh whole blood is preferred when available because it replaces volume, oxygen-carrying capacity, platelets, and plasma in one product; component therapy (packed red cells + plasma) is preferred in fixed facilities; and freeze-dried plasma had been "in development" as the far-forward solution for the field. That development is now operational.

Three differences between cFDP and human freeze-dried plasma matter for handler and medic training:

• Human blood products cause transfusion reactions in dogs. The major canine blood-group antigen DEA-1 is the analog of human ABO; transfusing unmatched human plasma into a dog risks hemolytic reactions. cFDP is canine plasma — pooled allogeneic, donor-screened, manufactured under FDA-reviewed quality systems.
• Single dog blood-group system is more permissive than human ABO. Dogs do not naturally carry preformed anti-DEA antibodies the way humans carry anti-A and anti-B isohemagglutinins; first-time transfusion can be performed without typing in an emergency. Subsequent transfusions risk alloimmunization and require matching. The 2019 JTS CPG is the authoritative reference on canine type-matching.
• Reconstitution is fast but not instantaneous. The Mantel kit reconstitutes the 20 g of lyophilized plasma in 250 mL of sterile water; published handling protocols and Mantel training materials describe reconstitution in roughly 3 to 5 minutes with gentle swirling. That is dramatically faster than thawing FFP (30 minutes from a -20°C freezer to usable IV product) but still slower than opening a unit of whole blood. Training matters.

Where does cFDP fit in the K9TCCC fluid resuscitation hierarchy?

The K9TCCC framework, published in the Journal of Special Operations Medicine in 2022, is the foundational doctrine document for working-dog casualty care under fire (Edwards et al., JSOM, 2022). The fluid section of K9TCCC mirrors the 2014 human TCCC fluid update that downgraded crystalloid in favor of blood products at the point of injury. Until December 2025, the practical reality at Role 1 K9 care was that the only fluid options available to a handler or unit medic were crystalloid or, in rare cases, a stocked unit of canine FFP that required a refrigerated freezer and thawing equipment. The new operational picture inserts cFDP between FWB and crystalloid as the realistic far-forward plasma option.

The integration question is not "do we use cFDP?" — it is "when do we use cFDP, and what does the rest of the resuscitation look like?" The K9TCCC framework answers that with a sequence that should be familiar to anyone who has trained on the human MARCH-PAWS algorithm:

1. Massive hemorrhage — direct pressure, hemostatic gauze, junctional pressure devices, tourniquet for limb wounds (canine-specific application). MED-TAC's K-9 Handler IFAK Kit is configured around this step.
2. Airway — positioning, foreign-body removal, surgical airway only with veterinary training.
3. Respiration — needle decompression for tension pneumothorax (different landmarks than human), occlusive dressing for sucking chest wounds.
4. Circulation — IV access (cephalic, lateral saphenous, intraosseous in proximal humerus), then blood product selection: FWB preferred, cFDP if FWB unavailable, crystalloid only as a last resort.
5. Hypothermia prevention — active warming with a thermal blanket; dogs in shock cool faster than humans because of higher surface-to-mass ratio.
6. Pain control — opioid (preferred) with veterinary oversight; NSAIDs avoided in trauma due to renal and platelet effects.
7. Wounds — irrigation and dressing per standard wound-care protocol.
8. Survey — full secondary survey en route to higher echelon of care.

cFDP is the "C" step's far-forward option. The dose typically targets 10 to 20 mL/kg of reconstituted plasma in shock, titrated to clinical response and reassessed with the same indicators used in human resuscitation: mental status, pulse quality, mucous membrane color and capillary refill, and (where available) lactate or shock index trends.

How does the Mantel cFDP kit work in the field, step by step?

The operational workflow is intentionally simple — the entire reason for freeze-dried plasma in the first place is that the field user does not need refrigeration, thawing, or a centrifuge. Training kits issued through the USAMMDA-Mantel partnership have been in stakeholder hands across the Department of Defense for over two years; the field workflow has been validated by exercises rather than improvised at the point of need (USAMMDA / Army.mil).

The step-by-step:

1. Indication confirmed. Class III or IV hemorrhagic shock, ongoing internal hemorrhage, or trauma-induced coagulopathy in a dog without rapid access to whole blood. The K9TCCC framework's shock recognition signs apply: weak or absent peripheral pulses, prolonged capillary refill (>2 seconds), mucous membrane pallor or grey, altered mentation, tachycardia in early shock progressing to bradycardia in decompensated shock.
2. IV or IO access. Cephalic vein at the front leg, lateral saphenous at the hind leg, or proximal humerus IO if vascular access is impossible. Pre-deployment training on canine vascular access is non-negotiable for any team carrying cFDP.
3. Reconstitute. Spike the cFDP bag with the supplied transfer set, introduce the 250 mL of sterile water for injection into the plasma bag, then gently swirl (do not shake — agitation can denature plasma proteins). Full reconstitution typically takes 3 to 5 minutes; published Mantel training materials describe inspecting the bag for complete dissolution before administration.
4. Administer. Through the supplied IV set. Initial dose is generally 10 to 20 mL/kg over 15 to 30 minutes, titrated to clinical response. Veterinary oversight directs the rate and total dose; the field user is administering on standing orders or telemedicine guidance.
5. Monitor. Watch for transfusion reaction — vomiting, urticaria, fever, dyspnea. Acute reactions to single-dose plasma in dogs are uncommon but documented; the prescribing veterinarian's protocol should include diphenhydramine and dexamethasone availability for mild reactions, and the team should be trained to stop the transfusion at the first sign of anaphylactoid reaction.
6. Continue MARCH-PAWS. cFDP is one component of resuscitation. Hemorrhage control, hypothermia prevention, and evacuation to definitive care continue in parallel.
7. Document and hand off. Record the dose, time of administration, lot number, and clinical response on the casualty card. The receiving veterinary team needs this information to plan subsequent transfusion strategy.

What injuries does cFDP actually treat, and what does it not fix?

The clinical scenarios that benefit:

• Penetrating trauma with hemorrhagic shock. The exact scenario the FDA cited in its update — gunshot wound, fragmentation injury, stab wound, severe lacerations from explosive blast — where the dog has lost enough blood to drive shock physiology and the bleeding source has been controlled enough to make resuscitation worthwhile.
• Blunt trauma with internal hemorrhage. Vehicle strike, building collapse, fall from height — situations where the bleeding source is internal and surgical, and the resuscitation goal is to keep the dog alive long enough to reach surgical care.
• Trauma-induced coagulopathy. Even when the bleeding looks controlled, severe trauma activates fibrinolysis and consumes clotting factors. cFDP replenishes those factors and, paired with tranexamic acid where veterinary protocols allow, can reverse the coagulopathic phase of trauma.
• Coagulopathic bleeding from envenomation. Some pit viper envenomations cause disseminated intravascular coagulopathy in dogs; antivenom is the definitive treatment but plasma provides factor support during stabilization.

The scenarios where cFDP is the wrong tool:

• Anemia without acute hemorrhage. A dog with chronic anemia needs red cells, not plasma. cFDP carries no oxygen.
• Septic shock without coagulopathy. Volume resuscitation and antibiotics are the priorities; plasma adds nothing.
• Hypovolemia from dehydration or heat injury without bleeding. Crystalloid is the right product; plasma is overkill and expensive.
• Pulmonary edema or volume-overloaded states. Adding plasma worsens the problem.
• Substitute for hemorrhage control. If the bleeding is not controlled, plasma is being lost as fast as it is administered. Tourniquet, hemostatic gauze, and direct pressure are the antecedent steps; plasma comes after.

How should a unit or K9 team prepare to integrate cFDP into a tactical or LE program?

The MED-TAC K-9 Handler IFAK Kit and K-9 Tactical Field Kit are designed around the hemorrhage-control and airway-respiration steps that precede transfusion. The cFDP kit is a third-layer asset — typically carried at the squad or vehicle level by a designated handler or medic who has been trained on reconstitution, IV/IO access, and the prescribing veterinarian's standing order. Civil-side teams (police K9, federal agency, search-and-rescue) have the same workflow under a civilian veterinary medical director instead of a unit veterinarian.

The training curriculum that experienced K9TCCC programs are running:

• Vascular access on a canine task trainer. Cephalic, lateral saphenous, and proximal-humerus IO. Live-tissue training where permitted, with appropriate veterinary supervision and IACUC approval.
• Reconstitution drills. Repeated reconstitution of expired or simulated cFDP kits under time pressure. The first time a handler reconstitutes cFDP should not be on an actual casualty.
• K9TCCC integrated scenarios. Penetrating trauma simulation in low-light, with hemorrhage control, IV access, cFDP reconstitution, hypothermia management, and evacuation timed as a single continuous event.
• Transfusion-reaction recognition and treatment. What it looks like, when to stop, how to manage with the veterinarian's standing meds.
• Documentation. Casualty card discipline so the receiving veterinary team has the data it needs.

For procurement — particularly for federal and law-enforcement K9 programs — the regulatory and acquisition pathway is still developing. MED-TAC's Government Procurement Solutions page is the routing path for any Fire, EMS, police, or military K9 program that needs a quote on K9 trauma kits, handler IFAKs, and the supporting training equipment that should precede a cFDP fielding decision.

How does this fielding moment fit into the broader trajectory of working-dog combat medicine?

The 2023 Army.mil article on the USAMMDA-Mantel partnership documents the gap directly. Lt. Col. Charles Bane, USAMMDA Force Health Protection Director and a veterinarian who had himself deployed with working dogs, stated that the pre-deployment medical kits he prepared as a Special Forces Group veterinarian "did not include any kind of canine blood product" and that "blood therapy, whole or component, would not be seen until reaching a Role 2 site." The development of cFDP — with its at-least-one-year shelf life and field-portable reconstitution — was the engineering solution to that doctrine gap. The five training kits fielded to DoD stakeholders in 2023 set the operational stage for the December 2025 regulatory decision (USAMMDA / Army.mil).

The broader trajectory of working-dog medicine over the last decade follows the human casualty-care pattern: the lessons learned in combat propagate to civilian operational use. K9TCCC follows TCCC. Canine tourniquet protocols follow human tourniquet protocols. Hemorrhage-control hemostatics follow the same manufacturer pipeline. cFDP follows the human freeze-dried plasma pathway. Each step shortens the time from injury to definitive resuscitation for the dog and brings the standard of canine combat casualty care closer to the standard of human combat casualty care. The Tennessee and Florida legislative moves on K9 emergency care covered in the MED-TAC K9 Tactical Casualty Care 2026 piece document the civilian-side complement to this military-side fielding moment.

All products sourced from the actual brand manufacturer or authorized master distributors. CoTCCC recommendation status verified where applicable. Ships from MED-TAC International, Pembroke Pines, FL — clinician-founded, veteran-led, SDVOSB-certified.